Prevail Therapeutics to Present at Upcoming Investor Conferences
September 02, 2020 17:18 ET
|
Prevail Therapeutics
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
August 11, 2020 06:30 ET
|
Prevail Therapeutics
Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients Company Modifies Protocol for PROPEL...
Prevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Conference
August 05, 2020 16:31 ET
|
Prevail Therapeutics
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
August 05, 2020 16:01 ET
|
Prevail Therapeutics
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006
July 27, 2020 16:05 ET
|
Prevail Therapeutics
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
July 22, 2020 17:01 ET
|
Prevail Therapeutics
Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Overview of Planned Phase 1/2 PR006...
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
June 04, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference
May 26, 2020 16:01 ET
|
Prevail Therapeutics
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
May 21, 2020 17:46 ET
|
Prevail Therapeutics
CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company...
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights
May 14, 2020 07:00 ET
|
Prevail Therapeutics
Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup ActivitiesProgressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic Gaucher Disease and PR006...